- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05638295
Test af brugen af AMG 510 (Sotorasib) og Panitumumab som en målrettet behandling for KRAS G12C mutant solid tumorcancer (et ComboMATCH-behandlingsforsøg)
Et randomiseret fase II-studie af AMG 510 (Sotorasib) med eller uden Panitumumab i avancerede solide tumorer: Et ComboMATCH-behandlingsforsøg
This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Panitumumab is in a class of medications called monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. Giving combination panitumumab and sotorasib may kill more tumor cells in patients with advanced solid tumors with KRAS G12C mutation.
Studieoversigt
Status
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 (sotorasib) alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except colorectal carcinoma [CRC] and non-small cell lung carcinoma [NSCLC]) as measured by progression free survival (Cohort 1).
II. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by response rate (Cohort 2).
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except CRC and NSCLC) as measured by response rate, disease control rate, and overall survival (Cohort 1).
II, To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by disease control rate, progression free survival (PFS), and overall survival (Cohort 2).
III. To further evaluate the safety and tolerability of the combination of AMG 510 (sotorasib) and panitumumab.
IV. To collect tissue and provide it to the ComboMATCH Registration Protocol to assess concordance between the diagnostic tumor mutation profile generated by the Designated Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor-derived deoxyribonucleic acid (DNA) (ctDNA) mutation profile from plasma, as described in ComboMATCH Registration Protocol.
CORRELATIVE EXPLORATORY OBJECTIVES:
I. To investigate the impact of concomitant mutations on the clinical benefit. II. To evaluate if changes in circulating tumor DNA (ctDNA) over time correlate with response to treatment.
III. To evaluate the relative mutant allele fraction of KRAS mutation as a predictor of clinical benefit.
IV. To evaluate if ERK 1/2 and PI3K pathway activation correlate with response and/or resistance.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A or B.
ARM A: Patients receive sotorasib orally (PO) once daily (QD) on days 1-28 and panitumumab intravenously (IV) on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and computed tomography (CT) or magnetic resonance imaging (MRI) on study.
ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C.
ARM C: Patients receive combination therapy as in Arm A.
After completion of study treatment, patients are followed up at 30 days and then every 3-6 months for up to 36 months.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- University of Alabama at Birmingham Cancer Center
-
Mobile, Alabama, Forenede Stater, 36688
- University of South Alabama Mitchell Cancer Institute
-
-
California
-
Los Angeles, California, Forenede Stater, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Forenede Stater, 90025
- The Angeles Clinic and Research Institute - West Los Angeles Office
-
Palo Alto, California, Forenede Stater, 94304
- VA Palo Alto Health Care System
-
-
Florida
-
Aventura, Florida, Forenede Stater, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Forenede Stater, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Coral Springs, Florida, Forenede Stater, 33065
- UM Sylvester Comprehensive Cancer Center at Coral Springs
-
Deerfield Beach, Florida, Forenede Stater, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Hollywood, Florida, Forenede Stater, 33021
- UM Sylvester Comprehensive Cancer Center at Hollywood
-
Jacksonville, Florida, Forenede Stater, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, Forenede Stater, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Forenede Stater, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Forenede Stater, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Forenede Stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Forenede Stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Forenede Stater, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Forenede Stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forenede Stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Forenede Stater, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Forenede Stater, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Barrington, Illinois, Forenede Stater, 60010
- Advocate Good Shepherd Hospital
-
Chicago, Illinois, Forenede Stater, 60612
- University of Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Forenede Stater, 60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake, Illinois, Forenede Stater, 60014
- AMG Crystal Lake - Oncology
-
Danville, Illinois, Forenede Stater, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Forenede Stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forenede Stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Downers Grove, Illinois, Forenede Stater, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Forenede Stater, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Forenede Stater, 62401
- Carle Physician Group-Effingham
-
Elgin, Illinois, Forenede Stater, 60123
- Advocate Sherman Hospital
-
Hazel Crest, Illinois, Forenede Stater, 60429
- Advocate South Suburban Hospital
-
Libertyville, Illinois, Forenede Stater, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, Forenede Stater, 60048
- AMG Libertyville - Oncology
-
Mattoon, Illinois, Forenede Stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Forenede Stater, 60153
- Loyola University Medical Center
-
Normal, Illinois, Forenede Stater, 61761
- Carle Cancer Institute Normal
-
Normal, Illinois, Forenede Stater, 61761
- Carle BroMenn Medical Center
-
O'Fallon, Illinois, Forenede Stater, 62269
- Cancer Care Center of O'Fallon
-
Oak Lawn, Illinois, Forenede Stater, 60453-2699
- Advocate Christ Medical Center
-
Oak Lawn, Illinois, Forenede Stater, 60453
- Advocate Outpatient Center - Oak Lawn
-
Palos Heights, Illinois, Forenede Stater, 60463
- Advocate High Tech Medical Park
-
Park Ridge, Illinois, Forenede Stater, 60068
- Advocate Lutheran General Hospital
-
Shiloh, Illinois, Forenede Stater, 62269
- Memorial Hospital East
-
Springfield, Illinois, Forenede Stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forenede Stater, 62702
- Springfield Clinic
-
Springfield, Illinois, Forenede Stater, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Forenede Stater, 61801
- Carle Cancer Center
-
-
Iowa
-
Ankeny, Iowa, Forenede Stater, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Des Moines, Iowa, Forenede Stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Forenede Stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Forenede Stater, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- University of Kentucky/Markey Cancer Center
-
-
Maine
-
Brewer, Maine, Forenede Stater, 04412
- Lafayette Family Cancer Center-EMMC
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Forenede Stater, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, Forenede Stater, 20889-5600
- Walter Reed National Military Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Forenede Stater, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Forenede Stater, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Forenede Stater, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Forenede Stater, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Forenede Stater, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Forenede Stater, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Forenede Stater, 48124
- Corewell Health Dearborn Hospital
-
Farmington Hills, Michigan, Forenede Stater, 48336
- Corewell Health Farmington Hills Hospital
-
Flint, Michigan, Forenede Stater, 48503
- Hurley Medical Center
-
Flint, Michigan, Forenede Stater, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Forenede Stater, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Forenede Stater, 48503
- Cancer Hematology Centers - Flint
-
Lansing, Michigan, Forenede Stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Forenede Stater, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Forenede Stater, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Royal Oak, Michigan, Forenede Stater, 48073
- Corewell Health William Beaumont University Hospital
-
Royal Oak, Michigan, Forenede Stater, 48073
- Corewell Health Children's
-
Saginaw, Michigan, Forenede Stater, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Forenede Stater, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Forenede Stater, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, Forenede Stater, 48085
- Corewell Health Beaumont Troy Hospital
-
West Branch, Michigan, Forenede Stater, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Forenede Stater, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Forenede Stater, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Deer River, Minnesota, Forenede Stater, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Forenede Stater, 55805
- Essentia Health Cancer Center
-
Hibbing, Minnesota, Forenede Stater, 55746
- Essentia Health Hibbing Clinic
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic in Rochester
-
Sandstone, Minnesota, Forenede Stater, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Forenede Stater, 55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Cape Girardeau, Missouri, Forenede Stater, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Forenede Stater, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Forenede Stater, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forenede Stater, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Forenede Stater, 63136
- Siteman Cancer Center at Christian Hospital
-
-
Montana
-
Anaconda, Montana, Forenede Stater, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Forenede Stater, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Forenede Stater, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Forenede Stater, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Forenede Stater, 59901
- Logan Health Medical Center
-
Missoula, Montana, Forenede Stater, 59804
- Community Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Forenede Stater, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Forenede Stater, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Buffalo, New York, Forenede Stater, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Forenede Stater, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, Forenede Stater, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Forenede Stater, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Forenede Stater, 43228
- Doctors Hospital
-
Columbus, Ohio, Forenede Stater, 43215
- Grant Medical Center
-
Dayton, Ohio, Forenede Stater, 45415
- Dayton Physician LLC - Englewood
-
Delaware, Ohio, Forenede Stater, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Forenede Stater, 43015
- Grady Memorial Hospital
-
Dublin, Ohio, Forenede Stater, 43016
- Dublin Methodist Hospital
-
Dublin, Ohio, Forenede Stater, 43016
- Columbus Oncology and Hematology Associates
-
Kettering, Ohio, Forenede Stater, 45429
- Kettering Medical Center
-
Mansfield, Ohio, Forenede Stater, 44903
- OhioHealth Mansfield Hospital
-
Marion, Ohio, Forenede Stater, 43302
- OhioHealth Marion General Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, Forenede Stater, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Forenede Stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forenede Stater, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Thomas Jefferson University Hospital
-
Willow Grove, Pennsylvania, Forenede Stater, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Boiling Springs, South Carolina, Forenede Stater, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Forenede Stater, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Forenede Stater, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Forenede Stater, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Forenede Stater, 29605
- Prisma Health Cancer Institute - Butternut
-
Greer, South Carolina, Forenede Stater, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Forenede Stater, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City, South Dakota, Forenede Stater, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Bristol, Tennessee, Forenede Stater, 37620
- Bristol Regional Medical Center
-
Johnson City, Tennessee, Forenede Stater, 37604
- Regional Cancer Center at Johnson City Medical Center
-
Kingsport, Tennessee, Forenede Stater, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Forenede Stater, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Temple, Texas, Forenede Stater, 76508
- Scott and White Memorial Hospital
-
-
Virginia
-
Bristol, Virginia, Forenede Stater, 24201
- Ballad Health Cancer Care - Bristol
-
Charlottesville, Virginia, Forenede Stater, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Forenede Stater, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Forenede Stater, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98122
- Swedish Medical Center-First Hill
-
-
West Virginia
-
Charleston, West Virginia, Forenede Stater, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Appleton, Wisconsin, Forenede Stater, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Forenede Stater, 54806
- Duluth Clinic Ashland
-
Berlin, Wisconsin, Forenede Stater, 54923
- ThedaCare Cancer Care - Berlin
-
Burlington, Wisconsin, Forenede Stater, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Cudahy, Wisconsin, Forenede Stater, 53110
- Aurora Saint Luke's South Shore
-
Germantown, Wisconsin, Forenede Stater, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Forenede Stater, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Forenede Stater, 54311
- Aurora BayCare Medical Center
-
Janesville, Wisconsin, Forenede Stater, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Kenosha, Wisconsin, Forenede Stater, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Forenede Stater, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Forenede Stater, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marinette, Wisconsin, Forenede Stater, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Forenede Stater, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Forenede Stater, 53233
- Aurora Sinai Medical Center
-
Neenah, Wisconsin, Forenede Stater, 54956
- ThedaCare Regional Medical Center - Neenah
-
New London, Wisconsin, Forenede Stater, 54961
- ThedaCare Cancer Care - New London
-
Oshkosh, Wisconsin, Forenede Stater, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Oshkosh, Wisconsin, Forenede Stater, 54904
- ThedaCare Cancer Care - Oshkosh
-
Racine, Wisconsin, Forenede Stater, 53406
- Aurora Cancer Care-Racine
-
Shawano, Wisconsin, Forenede Stater, 54166
- ThedaCare Cancer Care - Shawano
-
Sheboygan, Wisconsin, Forenede Stater, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Forenede Stater, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Forenede Stater, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waupaca, Wisconsin, Forenede Stater, 54981
- ThedaCare Cancer Care - Waupaca
-
Wauwatosa, Wisconsin, Forenede Stater, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Forenede Stater, 53227
- Aurora West Allis Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-E5 based on the presence of an actionable mutation as defined in EAY191
-
Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the time of registration/randomization to the EAY191-E5 study
-
Patient must be >= 18 years of age
-
Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening assessment
-
Patient must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191-E5)
- NOTE: The current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website: www.ctsu.org (final URL pending)
- NOTE: Novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH registration protocol
-
Patient must have cytologically/histologically confirmed advanced/metastatic solid tumor
-
Patient must have progressed on at least one line of standard of care therapy in the advanced/metastatic setting
- NOTE: Patients who have progressed on a prior human epidermal growth factor receptor (EGFR) inhibitor will meet this criterion
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 (or Karnofsky performance status >= 60%)
-
Patient must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) documented by imaging obtained within 28 days prior to registration/randomization
-
Patient must not have any serious active infection within 4 weeks prior to EAY191-E5 registration/randomization (e.g., requiring hospitalization and/or intravenous [IV] antibiotics) or currently receiving oral or IV antibiotics for the treatment of infection. Patients receiving prophylactic antibiotics are eligible
-
Patient must have the ability to retain oral medication and not have any clinically significant gastrointestinal abnormalities that might alter absorption
-
Patient must not have any history of or current evidence of non-infectious interstitial lung disease (ILD)/pneumonitis
-
Patient must not have a history of allergic reactions attributed to either of the study agents or to agents of similar chemical or biologic composition
-
Patient must have completed full treatment cycle 21 days prior to EAY191-E5 registration/randomization if they have received prior chemotherapy, biological cancer therapy, radiation therapy or an investigational agent/device. Patients must have recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from any adverse events due to prior cancer therapy (with the exception of alopecia)
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration/randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for at least 6 months after the last dose of protocol treatment. Patients must not breastfeed while receiving protocol treatment and for one week (7 days) after the last dose of AMG 510 (sotorasib) and 2 months after the last dose of panitumumab
-
Patients must not have neuropathy ≥ grade 2 within 14 days prior to registration/randomization
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Human immunodeficiency virus (HIV)-infected patients no effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac history, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trail, patients should be class 2B or better
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 28 days prior to protocol registration/randomization)
-
Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase ([SGPT]) < 3 x institutional upper limit of normal (obtained ≤ 28 days prior to protocol registration/randomization)
-
Creatinine =< 1.5 x institutional ULN OR creatinine clearance > 50 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 mg/dL as per Cockcroft-Gault (obtained ≤ 28 days prior to protocol registration/randomization)
-
COHORT I: Patient must not have colorectal cancer or non-small cell lung cancer
-
COHORT I: Patient must not have been previously treated with a KRAS G12C inhibitor
-
COHORT II: Patient must have progressed after treatment at the recommended phase II dose (RP2D) of any KRAS G12C inhibitor
- NOTE: Patients on cohort 1 who experience progression on Regimen 2 (AMG 510 [sotorasib] alone) may be eligible to enroll on cohort 2 and receive combination treatment with panitumumab and AMG 510 (sotorasib). Patients must meet performance status requirements and laboratory values as above and must be begin treatment within 7 days of enrollment. Migration to cohort 2 must take place within 6 months of progression, with no intervening anti-cancer therapy given.
- NOTE: Cohort migration following disease progression is dependent on a slot being available. MATCHBox makes the new treatment assignment following initiation of a step 2 registration for this treatment trial
-
COHORT II: Patient must not have been previously treated with a KRAS G12C inhibitor in combination with an EGFR inhibitor
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Cohort I Arm A (sotorasib, panitumumab)
Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
Andre navne:
Undergo collection of blood
Andre navne:
Undergo CT scan
Andre navne:
Undergo tumor biopsy
Andre navne:
Given IV
Andre navne:
Given PO
Andre navne:
|
|
Aktiv komparator: Cohort I Arm B (sotorasib)
Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
Andre navne:
Undergo collection of blood
Andre navne:
Undergo CT scan
Andre navne:
Undergo tumor biopsy
Andre navne:
Given PO
Andre navne:
|
|
Eksperimentel: Cohort II (sotorasib, panitumumab)
Patients receive combination therapy as in Arm A. |
Undergo MRI
Andre navne:
Undergo collection of blood
Andre navne:
Undergo CT scan
Andre navne:
Undergo tumor biopsy
Andre navne:
Given IV
Andre navne:
Given PO
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free survival (PFS) (Cohort I)
Tidsramme: From registration to documented disease progression or death from any cause, assessed up to 3 years
|
PFS will be compared between the arms using a one-sided log rank test with 10% type I error. Cox's proportional hazards model will be used to estimate the PFS hazard ratio between the treatment arms and a two-sided 80% confidence interval will be reported (to correspond to the one-sided 10% type I error). Confidence intervals on most other quantities will use the two-sided 90% level. |
From registration to documented disease progression or death from any cause, assessed up to 3 years
|
|
Best objective response (Cohort II)
Tidsramme: From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
Will be evaluated using the criteria defined by Response Evaluation Criteria in Solid Tumors) version 1.1 for patients with solid tumors. |
From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
|
Overall response rate (ORR) (Cohort II)
Tidsramme: From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
The exact 90% confidence interval on the ORR (determined using the method of Atkinson and Brown) will be reported. If the number of analyzable cases is less than 35, a 5% one-sided test will still be used. |
From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall survival (OS) (Cohort I)
Tidsramme: Up to 3 years
|
OS distributions by treatment will be estimated and 90% confidence intervals on estimated rates at 6 and 12 months will be reported. The OS hazard ratio will be estimated using Cox proportional hazards model and a 90% confidence interval reported. |
Up to 3 years
|
|
ORR (Cohort I)
Tidsramme: Up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
Up to 3 years
|
|
Disease control rates (Cohort I)
Tidsramme: From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
|
PFS (Cohort II)
Tidsramme: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
|
OS (Cohort II)
Tidsramme: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Kristen R Spencer, ECOG-ACRIN Cancer Research Group
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Neoplasmer
- Neoplastiske processer
- Patologiske tilstande, tegn og symptomer
- Neoplasma Metastase
- Aminosyrer, peptider og proteiner
- Proteiner
- Undersøgelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Kirurgiske procedurer, operative
- Cytologiske teknikker
- Cytodiagnose
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Diagnostiske teknikker, kirurgisk
- Kemiteknikker, analytisk
- Spektrumanalyse
- Panitumumab
- Biopsi
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- Sotorasib
Andre undersøgelses-id-numre
- NCI-2022-09876
- U10CA180820 (U.S. NIH-bevilling/kontrakt)
- NCI-2022-09876 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- EAY191-E5 (Anden identifikator: CTEP)
- EAY191-E5 (Anden identifikator: ECOG-ACRIN Cancer Research Group)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .